Cajal Therapeutics

A lab that treats the brain like a search problem

Walk into Cajal Therapeutics today and you will not find people arguing about a single hypothesis. You will find people arguing about how to test ten thousand of them. That is the whole point.

The company sits on Eastlake Avenue in Seattle, a few dozen scientists deep, with one belief that organizes everything else: in neurodegeneration, the hard part was never making a molecule. The hard part was knowing which target in the brain was worth making a molecule against. Most of the field guesses. Cajal built tooling to stop guessing.

It is named, with some nerve, after Santiago Ramón y Cajal - the Spanish scientist who drew the first maps of the neuron and is generally credited with founding modern neuroscience. Borrowing his name is a statement of intent. He looked at the brain one cell at a time. They look at it thousands of targets at a time.

Brain drugs fail. Usually for an embarrassing reason.

Here is the uncomfortable truth about Alzheimer's and Parkinson's research: an enormous amount of money has been spent attacking targets that turned out not to matter. The biology is messy - spatial, temporal, cell-type specific. A target that looks promising in a dish can be irrelevant in the part of the brain where the disease actually starts.

The industry's polite term for this is "translational failure." The blunt version is that people were validating targets one at a time, slowly, and often wrong. Decades of effort, and the success rate stayed stubbornly grim.

Cajal's founders looked at that record and drew a slightly heretical conclusion. The bottleneck was not biology's complexity. It was that nobody had industrialized the step where you figure out which complexity matters.

Assemble the people who built the tools, then point them at the brain

The bet was about people first. Cajal's co-founders read less like a startup roster and more like a neuroscience hall of fame: Huda Zoghbi, who chairs the scientific advisory board; Anthony Zador and Charles Zuker, both names you find on foundational neuroscience papers. Around them, an operating team that had actually shipped drug-discovery platforms.

Running the company day to day are two co-CEOs. Andrew Dervan, MD, MBA, came out of Celgene and Bristol Myers Squibb, where he led cell-therapy and immuno-oncology deals, and - in a detail that tells you something - still sees patients as a clinical geneticist at the University of Washington. Ian Peikon, PhD, helped build the target-discovery platform at Kallyope and is a Venture Partner at Lux Capital. Rob Hershberg, MD, PhD, serves as executive chairman.

The founding team: a group that has, between them, probably forgotten more neuroscience than most companies will ever learn.

A platform first, a pipeline second

Most biotechs sell you a molecule. Cajal built a method, and the molecules are what the method produces. The platform stacks four things that rarely sit under one roof: integrative human genetics and multi-omics, highly multiplexed functional genomics, and - the showy part - industrialized whole-brain imaging. Run them together and you can take the thousands of candidate targets implicated in Parkinson's and Alzheimer's and systematically ask which ones actually do something.

That validation engine feeds a pipeline of small molecule and RNA medicines. The lead program, CTX001, is described as a first-in-class iron mobilizer - designed to restore iron transport and make iron available for the metabolic and cellular work that depends on it. It reflects a broadening of the company's thesis: from neurodegeneration specifically toward the larger idea of restoring homeostasis, including anemias of inflammation and other iron-related disorders. The brand shift from "Cajal Neuroscience" to "Cajal Therapeutics" is the tidy outward sign of that wider ambition.

Conviction, measured in dollars and names

A platform thesis is easy to write and hard to fund. Cajal's $96M Series A is the market's way of saying the bet is credible. Read the cap table and you see why it carries weight: Bristol Myers Squibb - the very company several founders came from - put money in, alongside drug-discovery specialist Evotec, plus Two Sigma Ventures, Alexandria Venture Investments and Dolby Family Ventures, behind co-leads The Column Group and Lux Capital.

The bench behind the bet

Chemistry, computation, development and capital - the four corners you need if a target is going to become a tablet.

Restore balance, not just block disease

The word Cajal keeps returning to is homeostasis - balance. It is a quietly radical framing. Much of drug development is about blocking a bad thing. Cajal's stated mission is about restoring a system that has drifted: iron that is no longer where the body needs it, energy and oxygen transport that have fallen out of tune, brain function that depends on both.

That is why the company could broaden from "neuroscience" to "therapeutics" without losing the plot. Anemias of inflammation, iron-related disorders, neurodegeneration - different organs, same underlying idea. Find what has fallen out of balance, and design medicine to put it back.

If the method works, the field changes

Here is the skeptic's fair question: plenty of companies promise to industrialize discovery, and biology has humbled most of them. Cajal has not yet shown the world a drug working in patients. The platform is the asset; the proof is still ahead.

But the upside is the kind worth taking seriously. If you can reliably tell which target matters before spending a decade and a billion dollars finding out the hard way, you do not just build one good company - you change the base rate for an entire field that has needed it badly.

So return to that room on Eastlake Avenue, the one full of people arguing about how to test ten thousand hypotheses instead of one. A few years ago, that argument did not have the tools to be settled. Now it does. Whether the answers turn into medicine is the thing left to prove - and the only thing Cajal Therapeutics is really being built to find out.